Persistence and effectiveness of guselkumab treatment in patients with moderate‐to‐severe plaque psoriasis in a non‐interventional real‐world setting: The SPRING study

Author:

Puig L.1ORCID,Daudén E.2ORCID,Cuervas‐Mons M.3ORCID,Novella C.3,Guisado C.3

Affiliation:

1. Department of Dermatology Hospital de la Santa Creu i Sant Pau Barcelona Spain

2. Department of Dermatology Instituto de Investigación Sanitaria (IIS‐HP) Hospital Universitario de La Princesa Madrid Spain

3. Medical Department Janssen Cilag, S.A. Madrid Spain

Abstract

AbstractBackgroundGuselkumab is a monoclonal antibody that blocks the IL‐23 pathway with proven efficacy and tolerability in the treatment of moderate‐to‐severe plaque psoriasis.ObjectivesTo assess the persistence, effectiveness and safety of guselkumab in patients with moderate‐to‐severe psoriasis in real clinical practice in Spain.MethodsSPRING was a Phase IV, retrospective and non‐interventional study analysing patients with moderate‐to‐severe plaque psoriasis who had initiated guselkumab under clinical practice conditions at least 12 months before inclusion in the study. The primary endpoint was persistence (non‐persistence: discontinuation or interruption ≥90 days). Effectiveness was assessed using the Psoriasis Area Severity Index (PASI) and Investigator Global Assessment (IGA). Dermatology Life Quality Index (DLQI) and safety were also evaluated.ResultsA total of 284 patients were included between September 2020 and June 2021. The 1‐year probability of persistence was 89.6% (86.1%–93.3%). The 1‐year probability of persistence was also calculated according to prior biologic treatment, being 90.3% for biologic‐naïve patients and 89.5% for patients who received one or more biologic therapies before guselkumab. Additionally, patients were also classified based on the frequency of the administration of guselkumab treatment; the 1‐year probability of persistence was 91.9% in patients receiving guselkumab according to the Summary of Product Characteristics and 89.3% in patients with lengthened intervals of administration. After 1 year, PASI 90 was achieved by 56.4% of patients, IGA 0/1 response and BSA <3% were achieved by 65.5% and 77.8% of patients, respectively, and 65.8% achieved a minimal clinically significant difference (>4‐point reduction) in the DLQI score at 1 year. Twenty‐six adverse reactions (4 of them serious) were reported in 16 patients.ConclusionsThis study suggests that guselkumab has high persistence in real clinical practice in Spain, independently of the previous biologic treatments and changes in the frequency of treatment. Effectiveness and safety are consistent with previously published data.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3